Policy Update August 2024

This Policy Update covers developments since the May Budget.

National Science Statement and new National Science Priorities

The much-awaited new National Science Priorities were released on Monday 12 August, and were accompanied by a Science Statement. They are available from the Department of Industry Science and Resources website.

The Science Statement has a strong emphasis on the role science can play in supporting and creating industry, with a strong focus on economic prosperity. This is to be achieved through missions, multidisciplinary research and breaking down siloes, guided by 5 imperatives:

1. Australian scientists, science institutions, and infrastructure shaping Australia’s science future
2. Science at the centre of Australian industry
3. A diverse, skilled workforce to underpin the translation of science into new industries
4. Embracing science to drive Australia’s regional and global interests
5. A science system prepared for future challenges

The new Statement provides an opportunity to position the health, disability and aged care sectors as an ‘industry’ that is vital to Australia’s future success and prosperity, as a means of aligning health and medical research more closely with the Statement.

The Statement also focuses on encouraging people to undertake STEM careers but there is little on supporting the existing research workforce. A lot about missions, multidisciplinary research and breaking down siloes.

Five national Science Priorities have also been identified:

- Transitioning to a net zero future
- Supporting healthy and thriving communities
- Elevating Aboriginal and Torres Strait Islander knowledge systems
- Protecting and restoring Australia’s environment
- Building a secure and resilient nation

Supporting healthy and thriving communities is a very broad priority, embracing social and environmental determinants, and building health literacy. It includes disability and ageing, as well as health and medicine more generally.

Modernising Human Tissue laws

On Thursday 14 August, the Attorney General, the Hon. Mark Dreyfus and Assistant Health Minister the Hon. Ged Kearney MP announced an inquiry by the Australian Law Reform Commission into Australian tissue donation laws. Largely the responsibility of the State and territories, the review will consider whether legislative reform is required to harmonise laws across the nation. The inquiry will include consideration of donation of tissue for scientific purposes. Further information on the Inquiry is expected to be provided on the ALRC’s website in coming weeks.

Australian Centre for Disease Control

While the interim Australian CDC has been operating within the Department of Health the Department has advised a new timeline for its development, to enable recommendations from the report of the COVID-19 Inquiry, due at the end of September, to be incorporated into the design, followed by further consultation. The establishment of the Australian CDC will be subject to the passage of legislation; the lack of funding for the CDC in this Budget indicates the Government does not expect it to start in this financial year.

Australia’s Economic Accelerator

Only available to universities and funded through the Education portfolio, the AEA is set to provide funding of $270 million over 2024/25, through two separate programs:

Round 1

Round 2

AEA Ignite

Proof of Concept (TRL2.3.4)

Max. $500,000 for 12 months

$60 m. open now

$30m. open Nov.24

AEA Innovate

Proof of Scale (TRL 5,6,7)

Max. $5m. for up to 2 years

$120m. open now

$60 m. early 2025

For AEA Ignite an industry partner is recommended and it is mandatory for AEA innovate.

The programs must fit within the Government’s seven Priority areas for investment:

- Value-add in Resources
- Agriculture, forestry & fisheries
- Medical Science
- Renewables & low emission tech
- Defence Capability
- Transport
- Enabling capabilities

In addition to being in one of these priority areas, The AEA Advisory Board for the Australia’s Economic Accelerator has set the investment plan for the AEA for 2024/25. As a result, any proposal must also fit one of the six focus areas selected by the Board:

- Critical and strategic minerals processing
- Sustainable fuels
- Digital agriculture
- Quantum
- Artificial intelligence
- Advanced manufacturing

The most likely ‘fits’ within the focus areas for medical science are going to be products which require advanced manufacturing or utilise AI.

The focus area may change when the AEA Advisory Board sets its new investment plan for 2025/26. More information is available here.

National HMR Strategy

The National HMR Strategy now has its own webpage.

‘The strategy will:

- cover the entire sector and include all levels of government, industry, philanthropy, academia and consumers

- strengthen and leverage Australia’s world-leading research capability.’

Several current activities have been brought under the umbrella of the National Health and Medical Research Strategy, including:

- The MRFF/MREA alignment
- The National One Stop Shop; and
- The health and medical research workforce audit

MRFF/MREA Alignment

The MRFF/MREA alignment is proceeding in two stages, with legislative change required to fully implement a merged administration of the MRFF and MREA, with both funds managed by the NHMRC. ‘In the interim, the NHMRC and the department are working together to address key concerns and issues while we consider options for implementation. This includes working together to better use existing advisory committees (eg MRFF will seek advice from NHMRC committees), developing and implementing policies together, and other efforts that better align the two funds without requiring formal governance reforms.’ [Consultation Summary Report, Next Steps.]

Strategic Examination of R&D

Announced on Budget night, the new strategic examination of Australia’s R&D system is intended ‘to determine how we can get more value from every taxpayer dollar invested in research, maximise the contribution of science and R&D to the broader economy and maintain our competitive edge.’ Led by the Science and Industry Minister, it is nonetheless be a whole of government review.

A secretariat has been set up within the Department of Industry Science and Resources, and Dom English has moved from the Department of Education to lead the Secretariat. Consultation on the terms of reference and the members of the independent panel has been undertaken but the results are not yet public.

With health and medical research representing 26% of all Australian R&D, Research Australia will continue to champion a focus on health and medical research as part of this review.

National Reconstruction Fund

Fulfilling an election promise, the legislation to create the National Reconstruction Fund (NRF) was passed in early 2023.

The NRF was initially scheduled to invest $15.0 billion over 7 years from 2023–24 to provide targeted co-investments in seven priority areas: resources; agriculture, forestry and fisheries sectors; transport; medical science; renewables and low emission technologies; defence capability; and enabling capabilities. It can provide debt, equity or guarantees, but does not provide grants. The NRFC’s first corporate plan is available here. With time running out to make initial investments in this financial year, the plan commits the NRF to making its first investments before the end of 2024. No investments have been publicly disclosed to date.

HTA Review

The Health Technology Assessment (HTA) Policy and Methods Review concluded on 4 May 2024. The HTA Review Reference Committee which was responsible for overseeing the HTA Review, held its final meeting on 2 May 2024 and its final report has been provided to the Minister for Health and Aged Care.

The Minister has yet to make the Review Report, or any response to the report, public.

Recent Submissions

Good Institutional Practice Guide

In May, the NHMRC released a draft Good Institutional Practice Guide, which seeks to provide guidance to NHMRC-funded institutions and NHMRC-funded researchers about good institutional practice ‘to promote open, honest, supportive and respectful institutional cultures conducive to the conduct of high-quality research’. Its development has been overseen by NHMRC’s Research Quality Steering Committee.

Research Australia made a submission to the NHMRC, directed to the CEO Professor Steve Wesselingh. While welcoming the Guide we indicated that awareness of practices and initiatives that can improve research culture is not the primary barrier to improving research culture; significant work has already been done to identify the issues and raise awareness. The key problem is implementing the measures needed to improve the culture.

We suggested the finalisation and publication of the Good Institutional Practice Guide will provide impetus for improvement that we can build on if we act collectively. Research Australia suggested leadership and involvement from the NHMRC will be essential, and would demonstrate the NHMRC’s ongoing commitment to improving research culture and practice. We offered to work with the NHMRC, the Research Quality Steering Committee, other peak bodies and research institutions that want to participate in a coalition to improve research practice and culture.

Allied health Workforce

In May the Department of Health and Aged Care released a consultation paper on a draft outline of the National Allied Health Workforce Strategy, intended to ensure there are enough highly trained allied health professionals distributed across the country.

Research Australia’s response to the consultation paper focussed on the need for the strategy to recognise the role of allied health professionals as clinician researchers in creating a self improving allied health sector and supporting retention of allied health professionals.

To achieve this the Strategy needs to better support clinician researchers and the submission highlighted ways to do this.

Upcoming Consultations and Submissions

Keep up to date with new consultations on the Research Australia website here.

All Research Australia’s submissions to closed consultations can be found here.

Improving Research Culture a collective responsibility

In May, the NHMRC released a draft Good Institutional Practice Guide which seeks to provide guidance to NHMRC-funded institutions and researchers about good institutional practice ‘to promote open, honest, supportive and respectful institutional cultures conducive to the conduct of high-quality research’. Its development has been overseen by NHMRC’s Research Quality Steering Committee.

Research Australia made a submission in response to the draft. While welcoming the Guide Research Australia indicated that awareness of practices and initiatives that can improve research culture is not the primary barrier to improving research culture; significant work has already been done to identify the issues and raise awareness. The key problem is implementing the measures needed to improve the culture.

Research Australia suggested the finalisation and publication of the Good Institutional Practice Guide will provide impetus for improvement that the sector can build on if we act collectively. Research Australia suggested leadership and involvement from the NHMRC will be essential, and would demonstrate the NHMRC’s ongoing commitment to improving research culture and practice. We offered to work with the NHMRC, the Research Quality Steering Committee, other peak bodies and research institutions that want to participate in a coalition to improve research practice and culture.

Research Australia’s submission is available here.

Pre Budget Submission calls for greater investment in health and medical research and innovation

Research Australia’s Pre Budget submission to the Treasurer ahead of the 2024 Budget has made the case for increased investment in Australian health and medical research and innovation to support a healthier and more prosperous Australia.

The Australian Government’s investment in R&D is below the OECD average.

There is an additional $323 million approved for release from the MRFF in 2024-25 that the Government is not investing in medical research and innovation.

The Universities Accord process provides the ideal opportunity to increase the investment in the NHMRC, ARC and indirect research costs.

We have advocated for a greater role for the Australian Centre for Disease Control, for the greater use of Government procurement to support Australian innovation, and for the full development of the National HMR strategy and workforce strategy.

Read Research Australia’s submission here.

Research is central to the Universities Accord

Research Australia’s submission to the Universities Accord Discussion paper responds to two key issues. The first relates to the career prospects and professional development of early and mid-career researchers. Research Australia proposes that this be a shared responsibility of research funders, universities, researcher managers and researchers. We also welcome further consideration of programs to support exposure to roles in industry and government during the completion of a higher degree by research.

The second relates to the funding for indirect research costs. We propose a new structure for the future funding of direct and indirect research costs and two distinct principles to guide the structure. We also propose that funding for national research infrastructure be included in these deliberations.

In each proposal we outline the case for how and why these issues should be addressed by an Accord between universities and the Commonwealth Government.

Research Australia’s submission is available here.

Making better use of GP Data and enhancing GP decision making

Most GPs these days use a practice management system (PMS), software which helps capture and manage patient information. Many of these systems also use AI enabled Clinical Decision Support (eCDS) software to support clinical decision making by suggesting possible diagnoses and treatments.

The Australian Government is investigating options for making greater use of data held in PMSs, and also the options for oversight of the quality of eCDS. Research Australia’s submission has provided examples of the types of research outcomes that can be achieved with GP data, and suggested how research could support the validation of eCDS and confidence in its effectiveness.

Research Australia’s submission is available here.

RESEARCH AUSTRALIA WELCOMES AUSTRALIA’S ECONOMIC ACCELERATOR TO SUPPORT MEDICAL RESEARCH AND INNOVATION

2 February 2022

Research Australia welcomes the announcement by Prime Minister Scott Morrison of the new $1.6b Australia’s Economic Accelerator (AEA) to enhance the commercialisation of Australia’s world-leading research and innovation.

Seamless support for research from discovery to commercialisation has been a key priority for Research Australia on behalf of its membership across the entire research pipeline, and a significant focus of Research Australia’s national consultation on a future National Health and Medical Research Strategy.

“The AEA program announced by the Prime Minister at the National Press Club is a solid step forward in addressing the well-known problem of the ‘valley of death’,” said Research Australia CEO Nadia Levin.

“Sustainable government funding like this moves us that bit closer towards developing a thriving research commercialisation and manufacturing ecosystem that benefits our health and economy,” Ms Levin said.

“At the moment we have a real issue with public funding not taking research far enough along the pipeline to make it attractive to commercial investors and/or commercial investors who are reluctant to invest in research at an earlier stage.

“Stronger connections between industry and research development along with encouraging mutually beneficial commercialisation partnerships between Australian universities, industry, and funders, can bring significant value for our innovation and export capabilities, and government plays a huge role in facilitating this,” Ms Levin said.

Research Australia also welcomes the announcement of industry PhDs and Fellowships, an initiative Research Australia has advocated for in the past. This is an important step in changing the research culture in Australia to give more researchers experience in industry.

“Our sector has long said there is a pressing need for training for university research staff in commercialisation, business development and developing research with industry and government. We’re hopeful that beyond the industry fellowships program, these issues can be addressed as part of a National Strategy for Health and Medical Research, announced by Health Minister, Greg Hunt at the Research Australia Awards in December.

“Research Australia looks forward to seeing the detail on how these programs will work and integrate with existing programs to provide effective and sustainable support across the entire pipeline of research from discovery to translation,” Ms Levin said.

Ensuring nationally coordinated, strategic investment in all stages of research has strong support from the sector under a future National Health and Medical Research Strategy.

“We are pleased to see the University Research Commercialisation Action Plan reinforce the importance of funding for basic research, however funding the full cost of research across the pipeline remains an issue.

“We will continue to advocate for increased funding across the research pipeline and the inclusion of Medical Research Institutes in the Accelerator, Industry PhD and Fellowships programs to ensure industry is able to engage more effectively with all of Australia’s publicly funded researchers,” Ms Levin said.

The issues facing funding for health and medical research are explored further by Research Australia here as part of our work on a new National Health and Medical Research Strategy. https://researchaustralia.org/health-and-medical-research-australia-can-do-better/strategic-coordination-of-funding-for-health-and-medical-research/

ENDS

Research Australia is the national peak body for health and medical research, representing stakeholders across the entire health and medical research pipeline. For more on Research Australia, go to: www.researchaustralia.org

Media contact: Peta Garrett – 0400 011 394

2022-23 Pre Budget Submission- a way forward

Research Australia’s 2022-23 Pre Budget Submission acknowledges the COVID-19 pandemic has had an enormous toll on the Australian community and globally, but also recognises that as a consequence of the way Australian governments and the community have responded, the impact in Australia has been comparatively mild.

Australia’s response to COVID-19 has been so broad and deep because of previous investments in the nation’s research and innovation capacity. This capacity, and the funding that underpins it, cannot be taken for granted. There is no guarantee that Australia’s health and medical research and innovation community will be equally well placed to respond to a future pandemic.

Research Australia’s submission makes the case for why maintaining and expanding this existing capacity for health and medical research and innovation is in the national interest.

In addition to raising national prosperity and diversifying our economy, smarter investment in health and medical research and innovation can improve the effectiveness of our health system; constraining the rise in health costs that accompany an ageing population. It can also provide a sustainable pathway to addressing modern lifestyle factors such as obesity. Smarter investment also drives skilled employment in vibrant new pharmaceutical, medical device and biotechnology industries.

Research Australia is advocating for an overarching national health and medical research strategy which ensures smarter, coordinated, strategic public investment in all stages of research; maximises impact on national priorities such as burden of disease, and the stronger translation of evidence-based research into healthcare delivery; and exploits areas of international competitive advantage. Imagining and preparing for the Australia we want in 50 years’ time has to start today.

Research Australia’ s submission is available here.

Medical Products Roadmap Consultation

Research Australia has responded to the consultation being undertaken by the Department of Industry, Science, Energy and Resources to support the development of a Medical Products Manufacturing Roadmap under the Modern Manufacturing Initiative announced in the October 2020 Budget. Medical products is one of six strategic areas being targeted under the MMI for Government spending of $1.3 billion over five years.

The Consultation was undertaken using an electronic survey restricted the length of the response to each question. Research Australia’s response emphasises:

- the opportunity to support the manufacture of products and materials for clinical trials;
- the opportunity this provides to scale to full scale manufacturing, keeping the full scale manufacturing of medical products developed in Australia on shore; and
- the opportunity to support manufacturing in high value medical products.

Research Australia’s submission is available here. These proposals were further developed in Research Australia’s January 2021 Pre Budget submission, available here.

The Government subsequently released the Medical Products National Manufacturing Priority Roadmap in February 2021. Research Australia’s proposal to support manufacturing for clinical trials as part of the Roadmap was adopted, and identified as a pathway to scaling up of manufacturing capability. The Roadmap is available here.

Medical technology investment to improve lives

11 September 2017

The Biomedical Translation Fund will fund three medical breakthroughs, as announced jointly by The Hon Greg Hunt MP, Health and Sports Minister and Senator The Hon Arthur Sinodinos, Minister for Industry, Innovation ad Science.

The investments are being made for the BTF by one of its three fund managers, BioScience Managers:

$5 million in Rex Bionics to develop a hands-free robotic device to help people with severe
disability to walk, exercise and rehabilitate;
$3.3 million to Saluda Medical for neuromodulation technologies for people suffering from
chronic back pain and other debilitating conditions;
$5 million to CHARM Informatics for data aggregation and commercialisation services for
makers of ‘smart’ medical devices.

A joint venture between the Australian Government and private sector investors, further investments are yet to be made, with a total of $500 million available.

Read the full media release about the Biomedical Translation Fund.

Continue reading “Medical technology investment to improve lives”

Why online health records help us all

Friday 1 September 2017

In an era of big data, the opportunity to harness the masses of information, including personal health records, through better collection, linkage and access, has the potential to transform our health systems and the way we deliver healthcare.

The more a doctor who is treating you knows about your medical history (and the quicker that history can be accessed) the better chance you have of it saving your life. If you are in an accident, unconscious and seriously hurt, then you really want those taking care of you to be able to access all your information about allergies, illnesses and medical history. It could make the difference between life and death.

You might assume doctors in various parts of the health system can already access your information, when the reality is that in most cases they cannot.The Australian health system is fragmented and information is not easily shared between the various GPs, medical specialists, private clinics and hospitals you visit over a lifetime. This means the data a medical professional looks at might not be complete or you may have to recall your own history repeatedly. This can lead to poor diagnoses and increased cost to the health system, with every repeat test and scan that might otherwise have been avoided.

Continue reading “Why online health records help us all”